Equities research analysts at Mitsubishi UFJ Financial Group initiated coverage on shares of Iqvia (NYSE:IQV) in a research report issued on Friday. The brokerage set a “neutral” rating and a $112.00 price target on the medical research company’s stock. Mitsubishi UFJ Financial Group’s price objective indicates a potential upside of 10.38% from the company’s previous close.
IQV has been the subject of a number of other reports. Mizuho cut Iqvia from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a research note on Thursday, November 9th. SunTrust Banks restated a “hold” rating and set a $114.00 price objective on shares of Iqvia in a research note on Friday, November 3rd. KeyCorp restated a “buy” rating and set a $100.00 price objective on shares of Iqvia in a research note on Sunday, September 24th. Credit Suisse Group restated an “outperform” rating and set a $110.00 price objective (up from $98.00) on shares of Iqvia in a research note on Monday, October 16th. Finally, Zacks Investment Research cut Iqvia from a “buy” rating to a “hold” rating in a research note on Friday, November 3rd. Ten research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $105.61.
Shares of Iqvia (NYSE IQV) opened at $101.47 on Friday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 1.22 and a current ratio of 1.22. The firm has a market capitalization of $21,260.52, a price-to-earnings ratio of 23.34, a P/E/G ratio of 1.63 and a beta of 0.61. Iqvia has a 12 month low of $74.73 and a 12 month high of $110.67.
In other news, insider James H. Erlinger III sold 10,000 shares of the stock in a transaction dated Wednesday, September 27th. The stock was sold at an average price of $94.52, for a total value of $945,200.00. Following the transaction, the insider now directly owns 27,340 shares of the company’s stock, valued at $2,584,176.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John Connaughton sold 1,030,429 shares of the stock in a transaction dated Tuesday, September 19th. The shares were sold at an average price of $94.87, for a total value of $97,756,799.23. The disclosure for this sale can be found here. Insiders have sold a total of 16,631,093 shares of company stock worth $1,640,970,687 over the last ninety days. 6.40% of the stock is currently owned by corporate insiders.
WARNING: This news story was originally posted by American Market News and is owned by of American Market News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/15/iqvia-iqv-now-covered-by-mitsubishi-ufj-financial-group.html.
About Iqvia
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
